{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapy%2C+Gene",
    "query": {
      "condition": "Therapy, Gene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1016,
    "total_pages": 102,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapy%2C+Gene&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T05:01:04.383Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07424157",
      "title": "Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "CAR T Cell",
        "CAR T Cell Therapy"
      ],
      "interventions": [
        {
          "name": "Long term follow up in all patients who received an SCTx gene therapy product",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 500,
      "start_date": "2026-06-15",
      "completion_date": "2041-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07424157"
    },
    {
      "nct_id": "NCT05241834",
      "title": "A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Thyroid Neoplasms"
      ],
      "interventions": [
        {
          "name": "LOXO-260",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2022-03-23",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241834"
    },
    {
      "nct_id": "NCT06152237",
      "title": "Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "TSHA-102",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Taysha Gene Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "8 Years",
        "sex": "FEMALE",
        "summary": "5 Years to 8 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2023-12-12",
      "completion_date": "2031-11-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Saint Paul, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06152237"
    },
    {
      "nct_id": "NCT03634007",
      "title": "Gene Therapy for APOE4 Homozygote of Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Early Onset Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "LX1001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lexeo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-11-06",
      "completion_date": "2024-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 4,
      "location_summary": "Maitland, Florida • Orlando, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03634007"
    },
    {
      "nct_id": "NCT06692712",
      "title": "Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Spastic Paraplegia Type 50"
      ],
      "interventions": [
        {
          "name": "MELPIDA",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Elpida Therapeutics SPC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "72 Months",
        "sex": "ALL",
        "summary": "4 Months to 72 Months"
      },
      "enrollment_count": 24,
      "start_date": "2026-04-01",
      "completion_date": "2032-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06692712"
    },
    {
      "nct_id": "NCT03664830",
      "title": "Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-09-19",
      "completion_date": "2026-08-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03664830"
    },
    {
      "nct_id": "NCT00910884",
      "title": "Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "therapeutic dietary intervention",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Brabant Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2020-09",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Spokane Valley, Washington",
      "locations": [
        {
          "city": "Spokane Valley",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910884"
    },
    {
      "nct_id": "NCT01440816",
      "title": "IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tavokinogene Telseplasmid (tavo)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OncoSec Medical System (OMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2012-01-03",
      "completion_date": "2015-04-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440816"
    },
    {
      "nct_id": "NCT00091104",
      "title": "Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1:27-35 peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2004-07",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091104"
    },
    {
      "nct_id": "NCT02225184",
      "title": "Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Genetic Underpinning of Substance Abuse",
        "Polymorphism-genetic",
        "Drug Abuse/Dependence",
        "Opiod-Related Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2014-08-23",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-07-24T05:01:04.383Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02225184"
    }
  ]
}